Allergan’s most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $175.00 short call and a strike $180.00 long call offers a potential 16.82% return on risk over the next 3 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $175.00 by expiration. The full premium credit of $0.72 would be kept by the premium seller. The risk of $4.28 would be incurred if the stock rose above the $180.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 30.21 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Fri, 10 Nov 2017 12:27:00 +0000
THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ — Amgen (AMGN) and Allergan plc. (AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin® (bevacizumab).
Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus
Thu, 09 Nov 2017 12:55:12 +0000
Increased operating expenses mar Aerie's (AERI) Q3 performance.
Allergan to Present Dynamic Eye Care Data at American Academy of Ophthalmology Meeting in New Orleans
Wed, 08 Nov 2017 13:00:00 +0000
DUBLIN , Nov. 8, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced its data will be presented at the annual American Academy of Ophthalmology (AAO) …
Why Neos Therapeutics Inc Rose 13.7% In October
Wed, 08 Nov 2017 11:00:00 +0000
The game of cat and mouse continues.
U.S. senators press Allergan for details on patent deal with tribe
Tue, 07 Nov 2017 20:51:30 +0000
Democratic Senators Sherrod Brown, Maggie Hassan, Amy Klobuchar, Al Franken and Patty Murray made the request for documents in a letter to Allergan Chief Executive Brent Saunders. Allergan contends the tribe’s status as a sovereign entity places the patents outside the jurisdiction of the U.S. Patent Trial and Appeal Board, or PTAB.
Also on Market Tamer…
Follow Us on Facebook